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1. Introduction 
Nitric oxide (NO) is produced in the endothelial cells, neurons, glia, and macrophages by 
the nitric oxide synthase (NOS) isoenzymes. Endothelial nitric oxide synthase (eNOS) is a 
subgroup of this family of enzymes that catalyze the production of nitric oxide (NO) from L-
arginine and oxygen, which causes vascular relaxation (1) by activates guanylate cyclase, 
which induces smooth muscle relaxation. 
The reaction catalyzed by eNOS is: 
L-arginine + 3/2 NADPH + H+ + 2 O2 = citrulline + nitric oxide + 3/2 NADP+ 
 
NO can also promote vasorelaxation indirectly by inhibiting the release of renin which 
converts angiotensinogen to angiotensin I. This is in turn cleaved to form active 
angiotensin II by Angiotensin-converting enzyme (ACE), the key component of the 
physiological control of blood pressure in human. Angiotensin II exerts its effects by 
binding to angiotensin II type 1, 2, 3, and 4 receptors (AT1R, AT2R, AT3R, AT4R). AT1R is 
the major mediator of physiological effects of angiotensin II. AT1R mediates its action by 
association with G proteins and followed by vasoconstriction. The activated receptor in 
turn couples to G proteins and thus activates phospholipases, increases the cytosolic  
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Ca2+ concentrations, which triggers cellular responses such as stimulation of protein 
kinases. Activated receptor also inhibits adenylyl cyclases and activates various tyrosine 
kinases (2). 
Ischemic stroke, caused either by thrombosis or embolism, is the most frequent disease 
leading to disability and/or to death (3). The genetic differentiations varying with ethnic 
properties may be related to the arrangement of the classic and non-classic risk factors for 
ischemic stroke (4). 
During the last two decades, there has been an increasing interest in the study of the 
different polymorphisms of genes of the renin-angiotensin system (RAS) and its association 
with the pathogenesis of stroke disease (5, 6). The RAS gene system comprises the 
angiotensinogen (AGT), renin, angiotensin I, angiotensin I-converting enzyme (ACE), 
angiotensin II, and angiotensin II receptors (7). 
The ACE is a key component of both the RAS and the kinin-kallikrein system. ACE cleaves 
the carboxy-terminal dipeptide of angiotensin I, releasing the physiologically active 
octapeptide angiotensin II (8). Angiotensin II is a potent vasoconstrictive molecule that plays 
a key role in modulating vascular tone. Angiotensin II exerts its effects by binding to the 
major mediator AT1R. Human AT1R is present predominantly in vascular cells and in both 
kidney and adrenal gland mediating physiological actions of angiotensin II. AT1R mediates 
its action by association with G proteins that activate a phosphatidylinositol-calcium second 
messenger system, followed by vasoconstriction, hypertrophy, or catecholamine liberation 
at sympathetic nerve endings (9). 
Our study aimed to assess the distribution of gene polymorphisms of ACE, AT1R and eNOS 
gene polymorphisms in ischemic stroke patients compared to healthy controls in the 
subjects from Trakya region. 
The ACE gene maps to chromosome 17 (17q23.3), spans 21 kb, and comprises 26 exons and 
25 introns, and is characterized by a polymorphism resulting from the presence (insertion) 
or absence (deletion) of a 287 base pairs fragment of a repeated Alu sequence at intron 16 
hence, the corresponding designation of insertion (I) or deletion (D) of the two resulting 
alleles (10, 11). 
The AT1R gene maps to chromosome 3 (3q21q25), spans 45.123 kb, and comprises 5 exons 
and 4 introns (12). AT1R entire coding region harbored only on exon 5, and is characterized 
by a polymorphism resulting from an A/C (adenine/cytosine) transversion located at 
position 1166 (A1166C polymorphism) in 3’ untranslated region (13). 
The eNOS gene is located on chromosome 7q35-36 and comprises 26 exons spanning 21 kb 
(14). Three classes of genetic polymorphisms in eNOS have been identified: those in intron 
regions, those in the promoter, and those in exon regions (15). 
The variable number of tandem repeat (27 VNTR) polymorphism in intron 4 of the eNOS 
gene (eNOS 4 a/b), and Guanine (G) to Thymine (T) conversion at nucleotide position 894 in 
exon 7 causing Glutamic acid (Glu) to Aspartic acid (Asp) change at 298 are two of the most 
encountered polymorphisms. This polymorphism was shown to affect the response of 
vascular endothelium and the NO levels of plasma (16, 17). 
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In view of the aging population stroke is becoming a major problem, it is the most frequent 
disease leading to disability (3) and estimates forecast a continuing increase in the incidence, 
prevalence, and mortality of stroke in the next decades. 
2. Material and methods 
The study included 341 subjects; 197 stroke patients and 144 controls (Table 1). All 
participants gave informed consent that was approved by the local ethics committee. DNA 
was isolated from peripheral blood, collected into tubes containing ethylenediamine-
tetraacetic acid (EDTA) by eZNA (EaZy Nucleic Acid Isolation) blood DNA kits (Omega 
Bio-tek, Doraville, USA). eNOS (4 a/b) and ACE (I/D) gene polymorphisms were identified 
using a polymerase chain reaction (PCR) technique (5, 18). The AT1R (A1166C) and eNOS 
(Glu298Asp) gene polymorphisms were identified using PCR technique and restriction 
fragment length polymorphism (RFLP) assay (5, 19). 
 
 Control Group Stroke Group p 
Hypertension (%) 61.3 83.1 <0.001 
Current smoker (%) 3.6 28.3 <0.001 
Diabetes mellitus (%) 17.6 33.8 0.001 
Family history of stroke (%) 17.6 33.0 0.002 
Age (years) 63.0 (17.0) 69.0 (14.0) <0.001 
SBP (mmHg) 120.0 (20.0) 140.0 (40.0) <0.001 
DBP (mmHg) 70.0 (10.0) 80.0 (20.0) <0.001 
FBG (mg/dl) 89.5 (18.3) 105.5 (41.0) <0.001 
TG (mg/dl) 117.5 (93.5) 145.0 (105.0) 0.008 
TC (mg/dl) 189.0 (44.0) 190.0 (52.0) NS 
HDL-C (mg/dl) 39.0 (19.5) 38.5 (14.0) NS 
LDL-C (mg/dl) 120.5 (35.0) 124.0 (41.5) NS 
SBP/DBP; Systolic/Diastolic blood pressure, FBG; Fasting blood glucose, TG; Triglycerides, TC; Total 
cholesterol, HDL-C/LDL-C; High/Low density lipoprotein cholesterol, NS: Non-significant. 
Table 1. Demographic and clinical characteristics of the control and stroke groups 
PCR technique, developed in 1983 by Kary Mullis, is an in vitro indispensable scientific 
technique used in medical genetics and hereditary disorders researches to amplify a single 
(or a few copies) of a piece of DNA to generating millions of copies of a particular DNA 
sequence (20). 
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The method relies on thermal cycling, consisting of steps of thermal cycling which can be 
accomplished automatically with the DNA thermal cycler. First step is DNA denaturation. 
DNA denaturation is necessary first to physically separate the two strands in a DNA double 
helix at a high temperature in a process called DNA melting. The four bases found in DNA 
are adenine (A), cytosine (C), guanine (G) and thymine (T). A base on one strand normally 
binds only to T on the other strand, and C base on one strand normally binds only to G on 
the other strand. The two types of base pairs form different numbers of hydrogen bonds, AT 
forming two hydrogen bonds, and GC forming three hydrogen bonds. To separate the tow 
strands of DNA, typical strand separation temperatures (Tss) are 95°C for 30 seconds, or 
97°C for 15 seconds (21). For G and C rich region higher temperature may be appropriate 
(21). The second step is primer annealing. Primers contain sequences complementary to the 
target region of the DNA template. Primer annealing is required for initiation of DNA 
synthesis at a lower temperature. A temperature of 55°C is a starting degree for 20 base 
primers with equal GC/AT content (22). Annealing temperatures in the range of 55°C to 
72°C generally yield the best results and occurs in a few seconds (21). The third step is 
primer extension. Primer extension depends upon the length of the target sequence. 
Extension at 72°C for fragments shorter than 500 base takes only 20 seconds, and fragments 
up to 1.2 kilo base 40 seconds is sufficient (23). 
In the PCR a thermostable Taq DNA polymerase, an enzyme originally isolated from the 
bacterium Thermus aquaticus, are used. The half life of Taq DNA polymerase activity is larger 
than 2 hours at 92.5°C, 40 minutes at 95°C, and 5 minutes at 97.5°C (21). This DNA 
polymerase enzymatically assembles a new DNA strand from deoxynucleotide 
triphosphates (dNTPs), by using separated single-stranded DNA as a template and DNA 
primers. Because the primer extension products synthesized in one cycle can serve as a 
template in the next, the DNA template is exponentially amplified. Thus, 20 cycles of PCR 
yields about a million - fold (220) amplification (22). Since strand dissociation temperatures, 
primer annealing, product specificity, and Taq DNA polymerase activity affected by 
magnesium concentration, the magnesium ion concentration was optimized for all gene 
amplifications in the study. Also, a recommended buffer for PCR is 10 to 50 mM Tris-HCl 
pH 8.3, up to 50 mM KCl, and up to 0.1% detergents such as Tween 20 must be included. 
The PCR products of a particular segment of DNA in an ethidium bromide stained agarose 
gel visualized by UV transillumination. The minimum amount which can be detected by UV 
transillumination is larger than 10 ng DNA. 
Restriction endonucleases are a set of enzymes expressed in bacteria against foreign DNA. 
Restriction enzymes cut or cleave double stranded DNA at specific recognition base 
sequences. In 1970 Smith H. et al identified the first restriction enzyme Hind II. Over 3000 of 
restriction enzymes have been isolated from different bacterial species (24, 25). Restriction 
enzymes can be used to distinguish single base changes in DNA (26). This method can be 
used to genotype a DNA sample without the need for expensive gene sequencing. The 
sample is first digested with the restriction enzyme to generate DNA fragments, and then 
the different sized fragments separated by gel electrophoresis. The choice of a restriction 
enzyme for PCR product is dictated by the product itself. All restriction enzymes require 
Mg2+ ions as a cofactor and 37°C is optimal for most of them to works. The recommended 
units and digestion buffer for 100% digestion with restriction enzymes is 10-20 units for 0.1 
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to 0.5 µg of PCR products and 10 mM Tris-HCl (pH 7.5 to 8.5), 10 mM MgCl2, 100 mM KCl 
and 0.1 mg/mL BSA. 
A genomic DNA were amplified by PCR technique in a total 25 µL PCR mixture 
containing 200 ng of DNA, deoxynucleotide triphosphates (0.2 mM of each), 0.5 nmol of 
sense and anti-sense oligonucleotide primers, 1X Taq buffer and 1.25 U of Taq DNA 
polymerase. eNOS (4a/b), ACE (I/D) and eNOS (Glu298Asp) gene polymorphism 
reactions were contained 2.5 mM MgCl2 whereas AT1R (A1166C) gene polymorphism 
reaction were contained 1.5 mM MgCl2. All reagents for PCR amplification and gel 
electrophoresis were purchased from Fermentas Life Sciences (ELİPS, Istanbul, Turkey). 
All other chemicals were from Sigma and Merck (BO&GA, Istanbul, Turkey) and of the 
highest purity available. DNA amplifications were performed with a Techne (TechGene) 
DNA Thermal Cycler. 
3. ACE I/D gene polymorphism (rs 4646994) 
The PCR primers with the sequences reported by Rigat B. et al. (27) were used. Sense and 
anti-sense primers were; 5’-CTGGAGACCACTCCCATCCTTTCT-3’ and  
5’-GATGTGGCCATCACATTCGTCAGAT-3’, respectively. Normally the sense primer in 
Rigat et al. didn’t contain (G), so our PCR products also didn’t contain (G), and the anti-
sense primer in Rigat et al. didn’t contain (G); which is normally must be included, but it 
was instead of (G) contained (A). Figure 1 shows the sequencing of the region which 
contains ACE (D) polymorphism. 
PCR Conditions 
 
The expected insertion (I) and deletion (D) alleles were visualized after electrophoresis on a 
2% agarose gel and ethidium bromide staining under UV light transillumination (Fig. 2). 
Preferential amplification of the D allele in the heterozygotes has led to their mistyping as 
DD homozygotes (28). To exclude this possibility, all DD homozygotes were retyped using I  
 
Fig. 1. The sequencing of the region which contains ACE (D) polymorphism. Italic and bold 
letters were used for the primer sequences. 
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allele specific sense primer 5’-TTTGAGACGGAGTCTCGCTC-3’ and anti-sense primer, also 
reported by Rigat B et al. (27) were used. Amplification was performed with a DNA 
Thermal Cycler with 3 min of denaturation at 93°C, followed by 30 cycles with 1 min of 
denaturation at 93°C, annealing for 1.5 min at 68°C, and extension for 2 min at 72°C, 
followed by 3 min of extension at 72°C. When a DD sample amplified using the I-specific 
primer, it was retyped ID. 
 
Fig. 2. PCR products of ACE gene I/D polymorphism. The DD (190 bp; lane 2, 5, 7, and 8), 
the ID (190 bp, and 490 bp, lane 3, 4, 6, 9, and 10) and the II (490 bp, lane 1), 50 bp is a size 
marker, (-) is a negatif control. 
4. eNOS 4 a/b (27 VNTRs) gene polymorphism 
The PCR primers with the sequences reported by Wang et al. (29) were used. Sense and anti-
sense primers were; 5’-AGGCCCTATGGTAGTGCCTT-3’ and  
5’-TCTCTTAGTGCTGTGGTCAC-3’, respectively. Figure 3 shows the sequencing of the 
region which contains eNOS 4 a/b (27 VNTRs) polymorphism. 
PCR Conditions 
 
The PCR products were electrophorized on 2.5% agarose gels, stained with ethidium 
bromide, and checked under UV light transillumination (Fig. 4). 
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Fig. 3. The sequencing of the region which contains eNOS 4 a/b (27 VNTRs) polymorphism. 
Italic letters were used for the primer sequences and bold letters were used for 27-bp repeats 
which are deleted in the VNTR 4a polymorphism. 
 
Fig. 4. PCR products of eNOS VNTR gene polymorphism. The aa genotype (394 bp; lane 1), 
the ab genotype (394 bp and 421 bp; lane 2), and the bb genotype (421 bp; samples 3, 4, and 
5). Lane (-) is a negative control, and 6 is a size marker (O’RangeRuler 100bp DNA Ladder). 
5. AT1R A1166C gene polymorphism (rs 5186) 
AT1R A1166C gene polymorphism was identified with PCR technique followed by RFLP 
with the restriction enzyme HaeIII (30). 
PCR primers were generated to amplify the 255 bp fragment encompassing the A1166C 
variant (sense and anti-sense primers were 5’-GCAGCACTTCACTACCAAATGGGC-3’ 
and 5’-CAGGACAAAAGCAGGCTAGGGAGA -3’, respectively) in a 25 µL PCR mixture. 
Figure 5 shows the sequencing of the region which contains AT1R A1166C gene 
polymorphism. The sense primer contains one mismatch (AńG) which was required for 
restriction site. 
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PCR Conditions 
 
The PCR products were electrophorized on 2% agarose gels, stained with ethidium bromide, 
and checked under UV light transillumination. 
 
Fig. 5. The sequencing of the region which contains AT1R A1166C polymorphism. Italic and 
bold letters were used for the primer sequences. The underlined and bold letters represent 
the restriction site for HaeIII (5’-GGŅCC-3’). 
 
Fig. 6. EtBr stained gel of HaeIII digested PCR products of AT1R A1166C shows the AA 
genotype (255 bp; lane 2, 3, 7, and 8), the AC genotype (255 bp, 231 bp, and 24 bp; lane 5, 6, 
9, and 11), the CC genotype (231 bp, and 24bp; lane 1, 4, and 10), lane O’GR is a size marker 
(100bp DNA Ladder). 
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Ten microliters of PCR product were digested with 5 unite of the restriction enzyme HaeIII 
(Takara Bio Inc, Japan) in 1 X M buffer (10 mM Tris-HCl, pH 7.5, 10 mM MgCl2, 1 mM 
Dithiothreitol and 50 mM NaCl) for 2 hours at 37°C. When mutant allele (cytosine), digested 
with HaeIII that yield two fragments, whereas a wild allele (adenine) at nucleotide position 
1166, had no cutting site for HaeIII, so that the PCR product was not cleaved into two 
fragments. The restriction digest products were visualized after electrophoresis on a 2.5% 
agarose gel and ethidium bromide staining (Fig. 6). 
6. eNOS Glu298Asp (rs 1799983) gene polymorphism 
Glu298Asp polymorphism of eNOS was identified with PCR technique followed by RFLP 
with the restriction enzyme BanII (19, 31).  
PCR primers were generated to amplify the 248 bp fragment encompassing the eNOS 
Glu298Asp variant primers 5’-AAGGCAGGAGACAGTGGATGGA-3’ (sense) and 5’-CCC 
AGTCAATCCCTTTGGTGCTCA-3’ (anti-sense). Figure 7 shows the sequencing of the 
region which contains eNOS Glu298Asp gene polymorphism. 
PCR conditions 
 
The PCR products were electrophorized on 2% agarose gels, stained with ethidium bromide, 
and checked under UV light transillumination. 
 
Fig. 7. The sequencing of the region which contains eNOS Glu298Asp polymorphism. Italic 
and bold letters were used for the primer sequences. The underlined and bold letters 
represent the restriction site for Ban II (5’-G(A/G)GC(T/C)ŅC-3’). 
Ten microliters of PCR product were digested with the restriction enzyme BanII to digest 
wild allele (guanine). When a guanine is at nucleotide position 894, resulting in a glutamic 
acid at amino acid position 298, BanII restriction enzyme produces two fragments of 163 and 
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85 bp. In contrast, when a thymine is at nucleotide position 894 (mutant allele), resulting in 
an aspartic acid in the amino acid sequence, the Asp298 variant had no cutting site for BanII, 
so that the 248 bp PCR product was not cleaved into 163 and 85 bp fragments. The 
restriction digest products were analyzed through electrophoresis on 2.5% agarose gel and 
ethidium bromide staining (Fig. 8). 
 
Fig. 8. EtBr stained gel of BanII digested products of eNOS gene Glu298Asp polymorphism. 
Line 1 and 4; GT alleles (85, 163, and 248 bp), line 2; GG alleles (85 and 163 bp), line 3; TT 
alleles (248 bp) and line 100bp; Gene Ruler 100 bp DNA Ladder. 
7. Results and discussion 
Table 2, 3, 4, and 5 shows the distributions of ACE I/D, eNOS (4 a/b), AT1R (A1166C), and 
eNOS Glu298Asp genotypes, respectively. 
Statistical analyses were performed with the SPSS 15.0 software and STATA program. 
Genotypic distributions were in accordance with Hardy-Weinberg equilibrium in the stroke 
group as well as in the control group. Several studies have shown differences in the 
genotypic distributions of these genes while, others have shown no differences between the 
controls and patients. Our results didn't show any significant difference between the 
ischemic stroke patients and the controls (p>0.05) and suggested the lack of an association 
between the 4 gene polymorphisms and ischemic stroke (Table 2, 3, 4, and 5). So the 4 gene 
polymorphisms did not enhance the predictability of stroke. 
 
 DD ID II 
Controls (%) 34.3 49.7 16.1 
Stroke Patients (%) 34.0 50.0 16.0 
 Non-Significant Non-Significant Non-Significant 
Table 2. Distribution of ACE (I/D) genotype frequency in the controls and stroke patients 
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 aa ab bb 
Controls (%) 2.8 29.8 67.4 
Stroke Patients (%) 2.0 35.0 63.0 
 Non-Significant Non-Significant Non-Significant 
Table 3. Distribution of eNOS (4 a/b) genotype frequency in the controls and stroke patients 
 
 AA AC CC 
Controls (%) 60.1 35.7 4.2 
Stroke Patients (%) 58.0 34.6 7.4 
 Non-Significant Non-Significant Non-Significant 
Table 4. Distribution of AT1R (A1166C) genotype frequency in the controls and stroke 
patients 
 
 GG GT TT 
Controls (%) 49.3 45.8 4.9 
Stroke Patients (%) 56.3 40.6 3.1 
 Non-Significant Non-Significant Non-Significant 
Table 5. Distribution of eNOS (Glu298Asp) genotype frequency in the controls and stroke 
patients 
In our previous study about potential angiotensinogen (AGT) gene that predispose to 
hypertension, we failed to detect any relation between T174M and M235T gene 
polymorphisms of the AGT gene in the RAS and the development of hypertension (32). 
Now, we are working on the AGT gene to clarify the role of T174M and M235T gene 
polymorphisms of the AGT gene in the stroke Turkish patients from Trakya region. 
8. Conclusions 
In addition to demographic and clinical characteristics, which are important in the 
developing of ischemic stroke, our data does not suggest that ACE (I/D), AT1R (A1166C), 
eNOS (4 a/b) and eNOS (Glu298Asp) gene polymorphisms, in contrast to other studies 
which shows a positive association between this gene polymorphisms and ischemic stroke, 
are a common cause of ischemic stroke in Turkish patients from Trakya region. 
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